NIDDK Central Repository - Baseline characteristics of participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial.

An official website of the United States government

NIDDK Central Repository

Publication Information

DOI

10.1053/j.ajkd.2008.08.010

PubMed ID

19022547

Public Release Type

Journal

Publication Year

2009

Affiliation

Rhode Island Hospital, 593 Eddy Street, Providence, RI 02903, USA.

Authors

Adey D, Alfrey E, Anil Kumar MS, Bolin P Jr, Bostom A, Bostom AG, Bresnahan B, Bunnapradist M, Carpenter MA, Cole E, Conti D, Cosio F, Danovitch G, Fabrega A, FAVORIT Study Investigators, Gallon L, House A, Hunsicker L, Jacques PF, Kasiske B, Kew C, Koch M, Kusek JW, Levey AS, Markell M, Matas A, McKenney JL, Mercier RY, Norman D, Ojo A, Pacheco-Silva A, Pesavento T, Pfeffer MA, Pirsch J, Selhub J, Singh A, Smith S, Vella J, Weir M, Yaqub MS

Studies

FAVORIT

Citation

Bostom AG, Carpenter MA, Hunsicker L, Jacques PF, Kusek JW, Levey AS, McKenney JL, Mercier RY, Pfeffer MA, Selhub J, FAVORIT Study Investigators. Baseline characteristics of participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. Am J Kidney Dis 2009 Jan;53(1):121-8. Epub 2008 Nov 20.

Abstract

Hyperhomocysteinemia may be a modifiable risk factor for the prevention of arteriosclerotic outcomes in patients with chronic kidney disease (CKD). Few clinical trials of homocysteine lowering have been conducted in persons with CKD before reaching end-stage renal disease. Kidney transplant recipients are considered individuals with CKD.